X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Winlevi (clascoterone) cream is an androgen receptor inhibitor, recently received approval form the TGA to commercilize in the australian market. It is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Through this merger, Sun Pharma will gain access to Taro's pipelines, enabling further commercialization in the market, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2024
Details:
The financing will be used to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems, including LYN-005 (risperidone), being developed for schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Lyndra Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Aclaris Therapeutics
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement December 05, 2023
Details:
CDSCO has approved Silodosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil (PDE5 inhibitor), a fixed dose combination for the treatment of benign prostatic hyperplasia.
Lead Product(s): Silodosin,Tadalafil
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2023
Details:
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Rytstat
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Zydus Lifesciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
Cequa (cyclosporine ophthalmic solution) is a patented, novel, proprietary nanomicellar NCELL formulation of cyclosporine in a clear, preservative-free, aqueous solution. It is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Cequa
Highest Development Status: Phase IVProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Winlevi (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tyvalzi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Pharmazz
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
